

ASX ANNOUNCEMENT

4 April 2022

Lapse of options

4 April 2022 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) confirms that, pursuant to agreements in place with option-holders, 20,983,371 options with an exercise price of \$0.46 and 145,007 options with an exercise price of \$0.945 were not exercised and automatically lapsed at 5pm on 31 March 2022. The options had been granted to holders of convertible notes at the time that those notes were converted into ordinary shares. An Appendix 3G confirming the lapse of these options will be lodged with the ASX shortly.

Authorised for release by the Company Secretary, Cann Group Limited.

For all media enquiries please contact:

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

For all other information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Deborah Ambrosini
CFO
Cann Group Limited
+61 3 9095 7088
deborah.ambrosini@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market a proprietary delivery system for cannabinoids. Cann has established research, cultivation and GMP manufacturing facilities in Melbourne and is finalising the construction of a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Learn more at: www.canngrouponlimited.com | www.satipharm.com